Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction

Prostate Cancer and Prostatic Diseases volume 21, pages 161–167 (2018)Cite this article

Subjects

Abstract

Background

The purpose of this narrative review is to evaluate the role of prostatic inflammation as a treatment target for lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO) and provide an update on the available therapies.

Methods

An extensive literature search was conducted for studies on established and investigational treatments with anti-inflammatory mechanism of action that has been assessed for the management of male LUTS due to BPO.

Results

Data on phosphodiesterase 5 inhibitors, nonsteroidal anti-inflammatory drugs, vitamin D3 receptor analogs, phytotherapy, statins, and lifestyle changes have been reviewed and analyzed. Preclinical evidence has shown the anti-inflammatory effect of these treatments on prostate. However, there is a wide variation in the degree of mature of each therapy. In addition, there are significant differences between the studies in terms of design, number of patients, and duration of follow-up.

Conclusions

Several drugs classes have been investigated for their impact on prostatic inflammation and improvement of male LUTS. The reviewed data support the rationale for use of agents that may alter and improve the inflammatory environment in the prostate in men with LUTS, but further high-quality long-term studies are required for the exact positioning of the new drugs in daily practice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37–49.

    Article  Google Scholar 

  2. Gravas S, Bach T, Drake M, Gacci M, Gratzke C, Herrmann TRW, et al. Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). http://uroweb.org/wp-content/uploads/EAU-Guidelines-Management-of-non-neurogenic-male-LUTS-2016.pdf. Accessed 15 Nov 2017.

  3. Chapple CR, Wein AJ, Abrams P, Dmochowski RR, Giuliano F, Kaplan SA, et al. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol. 2008;54:563–9.

    Article  Google Scholar 

  4. Robert G, Descazeaud A, Allory Y, Vacherot F, de la Taille A. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl. 2009;8:879–86.

    Article  Google Scholar 

  5. Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol. 2000;37:404–12.

    Article  CAS  Google Scholar 

  6. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164–75.

    Article  Google Scholar 

  7. Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109–15.

    Article  Google Scholar 

  8. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60:106–17.

    Article  Google Scholar 

  9. Wang L, Yang JR, Yang LY, Liu ZT. Chronic inflammation in benign prostatic hyperplasia: implications for therapy. Med Hypotheses. 2008;70:1021–3.

    Article  Google Scholar 

  10. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51:1202–16.

    Article  CAS  Google Scholar 

  11. Taoka R, Tsukuda F, Ishikawa M, Haba R, Kakehi Y. Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia. J Urol. 2004;171:2330–5.

    Article  CAS  Google Scholar 

  12. Russo GI, Cimino S, Castelli T, Favilla V, Gacci M, Carini M, et al. Benign prostatic hyperplasia, metabolic syndrome and non-alcoholic fatty liver disease: is metaflammation the link? Prostate. 2016;76:1528–35.

    Article  CAS  Google Scholar 

  13. Gacci M, Sebastianelli A, Salvi M, De Nunzio C, Vignozzi L, Corona G, et al. Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study. BMC Urol. 2017;17:22.

    Article  Google Scholar 

  14. Vignozzi L, Gacci M, Cellai I, Santi R, Corona G, Morelli A, et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate. 2013;73:789–800.

    Article  CAS  Google Scholar 

  15. Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis. 2013;16:101–6.

    Article  CAS  Google Scholar 

  16. De Nunzio C, Brassetti A, Gacci M, Finazzi Agrò E, Carini M, Presicce F, et al. Patients with prostatic inflammation undergoing transurethral prostatic resection have a larger early improvement of storage symptoms. Urology. 2015;86:359–65.

    Article  Google Scholar 

  17. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008;53:1228–35.

    Article  Google Scholar 

  18. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2005;174:1065–9.

    Article  Google Scholar 

  19. Gacci M, Andersson KE, Chapple C, Maggi M, Mirone V, Oelke M, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2016;70:124–33.

    Article  CAS  Google Scholar 

  20. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61:994–1003.

    Article  CAS  Google Scholar 

  21. Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, et al. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate. 2013;73:428–41.

    Article  CAS  Google Scholar 

  22. Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate. 2013;73:1391–402.

    Article  CAS  Google Scholar 

  23. Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology. 2000;56:671–6.

    Article  CAS  Google Scholar 

  24. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate. 2004;61:60–72.

    Article  CAS  Google Scholar 

  25. Minnery CH, Getzenberg RH. Benign prostatic hyperplasia cell line viability and modulation of JM-27 by doxazosin and ibuprofen. J Urol. 2005;174:375–9.

    Article  CAS  Google Scholar 

  26. Altavilla D, Minutoli L, Polito F, Irrera N, Arena S, Magno C, et al. Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia. Br J Pharmacol. 2012;167:95–108.

    Article  CAS  Google Scholar 

  27. Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of ran-domized controlled trials. BJU Int. 2013;111:304–11.

    Article  CAS  Google Scholar 

  28. Addla SK, Adeyoju AB, Neilson D, O’Reilly P. Diclofenac for treatment of nocturia caused by nocturnal polyuria: a prospective, randomized, double-blind, placebo-controlled crossover study. Eur Urol. 2006;49:720–6.

    Article  CAS  Google Scholar 

  29. Gokkaya GS, Aktas BK, Ozden C, Bulut S, Karabakan M, Erkmen AE, et al. Flurbiprofen alone and in combination with alfuzosin for the management of lower urinary tract symptoms. Cent Eur J Urol. 2015;68:51–56.

    Article  CAS  Google Scholar 

  30. Schenk M, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, et al. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2012;176:156–63.

    Article  Google Scholar 

  31. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001;54:935–44.

    Article  CAS  Google Scholar 

  32. Kang D, Andriole GL, van de Vooren RC, Crawford D, Chia D, Urban DA, et al. Risk behaviours and benign prostatic hyperplasia. BJU Int. 2004;93:1241–5.

    Article  CAS  Google Scholar 

  33. Nygård LH, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. Prostate. 2017;77:1029–35.

    Article  Google Scholar 

  34. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2010;33:475–88.

    Article  CAS  Google Scholar 

  35. Adorini L, Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol. 2007;103:689–93.

    Article  CAS  Google Scholar 

  36. Schroder A, Colli E, Maggi M, Andersson KE. Effects of a vitamin D(3) analogue in a rat model of bladder outlet obstruction. BJU Int. 2006;98:637–42.

    Article  Google Scholar 

  37. Colli E, Rigatti P, Montorsi F, Artibani W, Petta S, Mondaini N, et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol. 2006;49:82–86.

    Article  CAS  Google Scholar 

  38. Montorsi F, Colli E. Elocalcitol in the treatment of BPH: a multicenter, randomized, placebo-controlled phase IIb clinical trial. J Urol. 2008;179(Suppl):700–1. (abstract 2035)

    Article  Google Scholar 

  39. Keehn A, Lowe FC. Complementary and alternative medications for benign prostatic hyperplasia. Can J Urol. 2015;22(Suppl 1):18–23.

    PubMed  Google Scholar 

  40. de la Taille A. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116–23.

    Article  Google Scholar 

  41. Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen T. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:301–7.

    Article  Google Scholar 

  42. Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, López Farré A. BPH and inflammation: pharmacological effects of permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549–55.

    Article  CAS  Google Scholar 

  43. Latil A, Pétrissans MT, Rouquet J, Robert G, de la Taille A. Effects of hexanic extract of Serenoa repens (permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857–67.

    Article  CAS  Google Scholar 

  44. Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;12:CD001423.

    PubMed  Google Scholar 

  45. Novara G, Giannarini G, Alcaraz A, Cózar-Olmo JM, Descazeaud A, Montorsi F, et al. Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur Urol Focus. 2016;2:553–61.

    Article  Google Scholar 

  46. Mills IW, Crossland A, Patel A, Ramonas H. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol. 2007;52:503–9.

    Article  CAS  Google Scholar 

  47. Zhang X, Shen F, Dong L, Zhao X, Qu X. Influence and pathophysiological mechanisms of simvastatin on prostatic hyperplasia in spontaneously hypertensive rats. Urol Int. 2013;91:467–73.

    Article  CAS  Google Scholar 

  48. Lee SH, Park TJ, Bae MH, Choi SH, Cho YS, Joo KJ, et al. Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia. Korean J Urol. 2013;54:750–5.

    Article  Google Scholar 

  49. Zhang X, Zeng X, Dong L, Zhao X, Qu X. The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome. World J Urol. 2015;33:2071–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Department Mezourlo, University Hospital of Larissa, Larissa, 41100, Greece

    M. Samarinas

  2. Department of Urology, University of Florence, Viale Pieraccini 18, Florence, 50139, Italy

    M. Gacci

  3. Department of Urology, Robotic and Miniinvasive Surgery Assistance Publique des Hopitaux de Paris CHU Mondor – Faculté de Médecine, 54 av du Mal de Lattre de Tassigny, Créteil, 94000, France

    A. de la Taille

  4. Urology Department Mezourlo, University Hospital of Larissa, Larissa, 41100, Greece

    S. Gravas

Authors
  1. M. Samarinas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Gacci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. de la Taille
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Gravas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Gravas.

Ethics declarations

Conflict of interest

A.d.l.T.: Astellas, Bouchara-Recordati, GSK, Pierre Fabre Medicament. S.G.: Astellas, Angelini Pharma Hellas, GSK, Lilly, Pierre Fabre Medicament. M.G.: Astellas, Bayer, GSK, Ibsa, Konpharma, Lilly, Pierre Fabre Medicament, Pfizer. M.S. declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Samarinas, M., Gacci, M., de la Taille, A. et al. Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction. Prostate Cancer Prostatic Dis 21, 161–167 (2018). https://doi.org/10.1038/s41391-018-0039-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-018-0039-8

This article is cited by

Search

Advanced search

Quick links